What's your news flash? Send it to ed@edhat.com login  twitter  facebook  RSS 
 
 
 

 
News Events Referrals Deals Classifieds Comments About

Thoracic Aneurysm Research
updated: Jan 18, 2012, 4:21 PM

Source: Yale

A study by Yale School of Medicine reveals that survival rates for patients with a thoracic aneurysm are significantly better, and complications are fewer, among patients who take statin cholesterol drugs than those who do not. The study appears in the American Journal of Cardiology.

An aneurysm is a swelling of an artery, and is a common cause of death. It's usually asymptomatic, with death or a life-threatening complication such as rupture or dissection being the first manifestation. Statins are cholesterol- lowering drugs that are widely used in patients with cardiovascular disease.

Assistant professor of cardiothoracic surgery Ion S. Jovin, M.D., and colleagues studied 649 patients with thoracic aortic aneurysms: 147 were taking statins and 502 were not. In long-term follow-up 80% of those taking statins survived, compared with 67% percent of those not taking statins. In addition, a smaller percentage of those taking statins suffered a rupture or dissection (splitting of the aorta), compared to those who were not taking statins.

"The intake of statins was associated with an improvement in long-term outcomes among these patients," said co-author John Elefteriades, M.D., professor of cardiothoracic surgery at Yale School of Medicine and director of the Aortic Institute at Yale-New Haven Hospital. "In addition to better survival, fewer patients taking statins required surgical intervention," Elefteriades added.

Medical science has searched for decades for a medicine that could treat aneurysm disease, with little success. The current standard therapy is to keep blood pressure low to discourage rupture of the enlarged artery. Jovin said his research suggests that "statins could offer a significant protective effect to patients at risk of death or complications from aneurysm disease. However, the ultimate proof would be a randomized clinical trial." Elefteriades adds, "We now have some arrows in our quiver of medicines to treat this disease."

Other authors are Mona Duggal, Keita Ebisu, Hyung Paek, A. Dana Oprea, Maryann Tranquilli, John Rizzo, Redin Memet, Marina Feldman, James Dziura, and Cynthia A. Brandt of Yale.

This work was partly funded by the Yale Clinical and Translational Science Award grant from the National Center for Advancing Translational Sciences at the National Institutes of Health.

Comments in order of when they were received | (reverse order)

 

Add Your Comments

Edhat Username

Password

Comment

Don't have an Account?

Don't know if you have an account?

Don't remember your account info?

CLICK HERE


ENJOY HAPPY HOUR! ... Between 4:00pm & 5:00pm only happy comment are allowed on the Edhat Comments Board.

If you can't say something nice, don't say nothing at all.

 
Hide Your Handle
NOTE: We are testing a new Comment Preview Page. You must hit OK on the next page to have your comment go live. Send Feedback to ed@edhat.com.
 

get a handle   |  lost handle

 

EDHAT COMMENTS POLICY

 

# # # #

 

Send To a Friend
Your Email
Friend's Email

Top of Page | Printer-Friendly Page

MY NAME
  Home Subscribe FAQ Jobs Contact copyright © 2003-2015  
Edhat, Inc.